These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 2226500

  • 21. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
    Jones RN, Barry AL.
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185
    [Abstract] [Full Text] [Related]

  • 22. Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.
    Barrett MS, Jones RN.
    Diagn Microbiol Infect Dis; 1992 Oct; 15(8):685-91. PubMed ID: 1478049
    [Abstract] [Full Text] [Related]

  • 23. Antibacterial activity of cefpodoxime in vitro.
    Liu YC, Huang WK, Cheng DL.
    Chemotherapy; 1997 Oct; 43(1):21-6. PubMed ID: 8996737
    [Abstract] [Full Text] [Related]

  • 24. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
    Dan M, Poch F, Edelman A, Asherov J, Hafely H, Atzmon Y.
    J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
    [Abstract] [Full Text] [Related]

  • 25. In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
    Stewart AG, Bauer MJ, Butkiewicz D, Hinton A, Henderson A, Harris PNA, Paterson DL.
    Int J Antimicrob Agents; 2023 Aug; 62(2):106858. PubMed ID: 37211261
    [Abstract] [Full Text] [Related]

  • 26. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB.
    Pharmacotherapy; 1997 Aug; 17(1):121-5. PubMed ID: 9017772
    [Abstract] [Full Text] [Related]

  • 27. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.
    Bauernfeind A.
    Diagn Microbiol Infect Dis; 1991 Aug; 14(1):89-92. PubMed ID: 2013215
    [Abstract] [Full Text] [Related]

  • 28. Absence of a post-antibiotic effect (PAE) of beta-lactams against Helicobacter pylori NCTC 11637.
    Hassan IJ, Stark RM, Greenman J, Millar MR.
    J Antimicrob Chemother; 1998 Nov; 42(5):661-3. PubMed ID: 9848453
    [Abstract] [Full Text] [Related]

  • 29. PBP binding and periplasmic concentration as determinants of the antibacterial activities of three new oral cephalosporins in Escherichia coli.
    Cornaglia G, Ligozzi M, Bauernfeind A, Satta G, Fontana R.
    New Microbiol; 1994 Jul; 17(3):203-10. PubMed ID: 7968655
    [Abstract] [Full Text] [Related]

  • 30. Comparative antimicrobial activity of ceftibuten against multiply-resistant microorganisms from Belgium.
    Verbist L, Jacobs J, Hens K.
    Diagn Microbiol Infect Dis; 1991 Jul; 14(1):53-61. PubMed ID: 1901535
    [Abstract] [Full Text] [Related]

  • 31. Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes.
    Limnios A, Tapsall J, Kahlmeter J, Hogan T, Ray S, Lam A, Unemo M.
    APMIS; 2011 Jun; 119(6):356-63. PubMed ID: 21569093
    [Abstract] [Full Text] [Related]

  • 32. Clinical role of cefixime in community-acquired infections.
    Chemotherapy; 1998 Sep; 44 Suppl 1():35-8. PubMed ID: 9797423
    [No Abstract] [Full Text] [Related]

  • 33. In vitro susceptibility of Haemophilus influenzae to cefaclor, cefixime, cefetamet and loracarbef.
    Williams JD, Powell M, Fah YS, Seymour A, Yuan M.
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):748-51. PubMed ID: 1425737
    [Abstract] [Full Text] [Related]

  • 34. Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo.
    Chachaty E, Depitre C, Mario N, Bourneix C, Saulnier P, Corthier G, Andremont A.
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2009-13. PubMed ID: 1416894
    [Abstract] [Full Text] [Related]

  • 35. [Cefixime, the first oral third-generation cephalosporin].
    Roche G.
    Presse Med; 1989 Oct 11; 18(32):1541-4. PubMed ID: 2530527
    [Abstract] [Full Text] [Related]

  • 36. Overview of the clinical features of cefixime.
    Adam D.
    Chemotherapy; 1998 Sep 11; 44 Suppl 1():1-5. PubMed ID: 9797415
    [Abstract] [Full Text] [Related]

  • 37. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B, Luhmer E, Zühlsdorf MT.
    Drugs; 1991 Sep 11; 42 Suppl 3():6-12. PubMed ID: 1726210
    [Abstract] [Full Text] [Related]

  • 38. A critical review of the new oral cephalosporins. Considerations and place in therapy.
    Rodman DP, McKnight JT, Anderson RL.
    Arch Fam Med; 1994 Nov 11; 3(11):975-80. PubMed ID: 7804480
    [Abstract] [Full Text] [Related]

  • 39. [In vitro comparative effect of cefixime and 7 other beta-lactamines against Streptococcus pneumoniae].
    Boussougant Y, Weber P.
    Presse Med; 1989 Oct 11; 18(32):1553-5. PubMed ID: 2530530
    [Abstract] [Full Text] [Related]

  • 40. Comparison of cefpodoxime proxetil and cefixime in the treatment of acute otitis media in infants and children. Otitis Study Group.
    Asmar BI, Dajani AS, Del Beccaro MA, Mendelman PM.
    Pediatrics; 1994 Dec 11; 94(6 Pt 1):847-52. PubMed ID: 7971000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.